Fibrotic diseases are major causes of morbidity and mortality, and the epithelialmesenchymal transition (EMT) plays a central role in the development of tissue/organ fibrosis.
Introduction
Fibrosis is a complex disease state in which elevated proliferation of myofibroblasts is accompanied by overproduction of extracellular matrix (ECM) components (Bonnans et al., 2014) . Two fibrotic conditions, idiopathic pulmonary fibrosis (IPF) and liver fibrosis preceded by non-alcoholic steatohepatitis (NASH), affect many people around the world, and thus represent an urgent medical need. To date, however, no curative drugs for these conditions have become available (Fallowfield, 2015; Sgalla et al., 2016) . Two small-molecule anti-fibrotic drugs, pirfenidone (Esbriet) and nintedanib (Ofev), have recently been approved for IPF (King and Nathan, 2015) , but their efficacies and side effects must be improved to successfully treat this disease. Moreover, while nintedanib is an angio-kinase inhibitor, mode of action of pirfenidone exerting their anti-fibrotic activities remain to be elucidated.
Flavones are members of the polyphenol family, a group of >10,000 compounds predominantly found in the plant kingdom (Dixon and Pasinetti, 2010) . In general, these phytochemicals protect plants from radiation damage (Stapleton and Walbot, 1994) . Due to their anti-oxidant and anti-inflammatory potentials, flavones have long been used to treat inflammatory diseases such as arthritis and asthma (Leyva-López et al., 2016) . Chromone, 1,4-benzopyrone-4-one, is a central chemical scaffold constituting flavones (Emami and Ghanbarimasir, 2015) , and the chromone derivatives (CDs) are a diverse family based on branching chemical residues coupled to this core chemical framework (Gacche et al., 2015) .
We recently reported that eupatilin, a CD from an Artemisia species, dramatically inhibits osteoclastogenesis (Kim et al., 2015) and downregulates multiple genes associated with the epithelial-mesenchymal transition (EMT). Specifically, 24 of the 50 top genes differentially regulated by eupatilin are associated with the EMT, prompting us to hypothesize that eupatilin can prevent fibrosis ( Figure S1 ).
Here, we show that eupatilin can block induction of EMT or cell growth arrest and alter cell morphology, thereby substantially ameliorating lung fibrosis. This observation opens a door as a powerful new therapeutic modality for treating IPF.
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Results and discussion
Eupatilin has potent anti-fibrogenic capacity
We first investigated whether TGF-mediated fibrogenesis could be inhibited by CDs, particularly eupatilin, in human lung fibroblasts derived from IPF patients (hereinafter DHLFs:
Diseased Human Lung Fibroblasts) (Huang et al., 2014) . Compared with TGF alone, costimulation of DHLFs with TGF plus eupatilin resulted in significant growth arrest and morphological change (Figure 1A and S2A) . Currently, pirfenidone and nintedanib are the only targeted drugs approved for use in treating IPF (du Bois, 2010) . Two different concentrations of nintedanib completely blocked myofibroblastogenesis, whereas pirfenidone had no effect ( Figure S2B ).
To examine the influence of these compounds on the EMT, we performed immunocytochemistry (ICC) to detect expression of -smooth muscle actin (SMA), a marker of EMT induction. DHLFs, presumably preconditioned in IPF patients, had a myofibroblastlike morphology in vitro and could intrinsically express SMA, which was slightly upregulated by TGF ( Figure 1B ). Co-stimulation of DHLFs with eupatilin and TGF, however, virtually eliminated SMA expression ( Figure 1B ). Among the EMT-associated genes upregulated in DHLFs are those encoding vimentin and periostin; the latter is an important regulator of ECM biogenesis that also serves as a ligand for integrin V3 (Morra and Moch, 2011). TGF substantially increased expression of both genes, but eupatilin negated their upregulation ( Figure 1C ). upregulate Snail and Vimentin, but these effects were substantially attenuated by eupatilin ( Figure S3 ). Moreover, cell morphology was changed dramatically in that the resultant cells became rounder, suggesting that eupatilin could reorganize cytoskeletal structures. Taken together, these data suggest that eupatilin inhibits proliferation and drives morphological change of DHLFs, thereby negatively regulating EMT. In previous work, we demonstrated that eupatilin does not promote cell death (Kim et al., 2015) .
Myofibroblasts play a pivotal role in collagen deposition in fibrotic tissues.
Differentiation of several progenitor cell types has been observed in lung tissues, but reports of in vitro lung fibrogenesis remain limited (Pretheeban et al., 2012) . To develop an efficient cell-based fibrogenesis assay, we established a mouse hepatic stellate cell (HSC) line, ONGHEPA1 ( Figure S4 ). HSCs are widely appreciated for their unique roles in initiation and perpetuation of liver fibrosis (Gabele et al., 2003) . ONGHEPA1 had a mesenchymal morphology, expressed GATA4 but not cytokeratin 18 ( Figure S4A and S4B), and expressed CD29, CD44, and CD106 on the cell surface ( Figure S4C ), strongly indicating that they are of mesenchymal origin. Based on these features, we concluded that ONGHEPA1 is a mouse primary HSC line.
When ONGHEPA1 cells were stimulated with TGF, full differentiation into myofibroblasts occurred within 12-24 hr, but eupatilin completely inhibited TGF-induced fibrogenesis at concentrations of 50 M or higher ( Figure S5A ). However, pretreatment of ONGHEPA1 with eupatilin for 1-6 hr did not diminish fibrogenesis, suggesting that TGF-elicited signal transduction in combination with eupatilin is necessary to blunt fibrogenesis ( Figure S5B ). Eupatilin did not alter phosphorylation of Smad2 or Akt, but it significantly Reversion of fibrosis by eupatilin 6 inhibited phosphorylation of Erk and marginally inhibited Smad3 after 12 hr of treatment; Erk phosphorylation recovered slightly at 24 hr ( Figure S6 ), an observation we do not currently understand. Erk (Xie et al., 2004) or Smad3 (Willis and Borok, 2007) has been reported to play a pivotal role in TGF-mediated induction of the EMT.
PDGFR signaling has also been implicated in fibrogenesis (Wu et al., 2013) . However, when ONGHEPA1 cells were subjected to differentiation, PDGF was incapable of driving differentiation in the presence of eupatilin (Figure S7A and S7B) . ICC experiments clearly demonstrated that strong SMA immunoreactivity induced by TGF stimulation was eliminated by eupatilin ( Figure 1D ) and the same pattern held true for real-time expression of Col111 ( Figure 1D ).
Nintedanib is an angio-kinase inhibitor that antagonizes TGFR, FGFR, and PDGFR, but the mode of action (MOA) of pirfenidone remains elusive (Wollin et al., 2015) . When we stimulated cells with TGF in the presence of one of these drugs, or eupatilin, we observed that eupatilin and nintedanib effectively curbed fibrogenesis by ONGHEPA1 cells, as in the case of DHLFs, albeit with slight morphological differences between the two drugs ( Figure 1E ). On the other hand, pirfenidone could not inhibit differentiation, implying that the MOAs of eupatilin and pirfenidone may differ through this in vitro differentiation setup. The degree of inhibition of SMA mirrored the anti-fibrogenic effects ( Figure 1F ). Taken together, these observations demonstrate that a chromone scaffold (CS)-containing compound, eupatilin, is a potent anti-fibrotic drug that can inhibit fibrogenesis during differentiation of HSCs into myofibroblasts largely by reprogramming EMT, leading to cell shape change. This conclusion in conjunction with the eupatilin-associated growth arrest and morphological changes in Reversion of fibrosis by eupatilin 7 DHLFs prompted us to investigate whether eupatilin could exert a therapeutic effect on IPF.
For this purpose, we used the mouse bleomycin-induced lung fibrosis (BILF) model.
Eupatilin significantly improved BILF
Eupatilin or pirfenidone at 100 mg/kg (mpk) was orally administered twice per day, followed by one intratracheal administration of bleomycin; daily oral drug intake continued for the next 14 days (Figure 2 ). At 100mpk, the molar concentrations of pirfenidone is 2 fold higher than eupatilin. Oral administration of pirfenidone over 100mpk exhibited hepatotoxicity such that we simply selected 100mpk for comparing therapeutic capacity between these two drugs. Each drug administration group consisted of eight mice. We observed significant reductions in the levels of soluble collagen and hydroxyproline as well as changes in collagen histomorphometry in the drug-treated animals ( Figure 2A , 2B, and 2C). Interestingly, the largest reduction in TGF production occurred in the pirfenidonetreated mice ( Figure 2D ), suggesting that the MOA of pirfenidone relates to downregulation of TGF production, presumably from immune cells. Fibrotic tissues are characterized by notable collagen deposition, along with proliferation or infiltration of myofibroblasts (Wynn, 2008) . To examine these processes, we performed H&E staining in such a way as to visibly stain proliferative and infiltrated cells and used Sirius red to stain regions of collagen deposition. As seen in Figure 2E , bleomycin-treated lungs harbored the largest number of H&E-and Sirius red-stained cells, and pirfenidone treatment weakened the intensities of both stains. More intriguingly, eupatilin-treated lungs contained the smallest number of fibrotic cells and very pale collagen staining, suggesting that eupatilin may seem to have more potent cell regeneration potential than pirfenidone ( Figure 2E ).
Next, to substantiate the anti-fibrotic potential of eupatilin, we examined the dose Reversion of fibrosis by eupatilin dependence of its effects. At doses of 100 and 200mpk, but not a lower dose of 50mpk, we observed a statistically significant improvement in the levels of soluble collagen and hydroxyproline. Overall, pirfenidone 100mpk had less of an inhibitory effect on collagen histomorphometry, soluble collagen, and hydroxyproline than eupatilin 200mpk, and this difference was also statistically significant ( Figure 3A and 3B). Notably in this regard, the molar concentrations of eupatilin 200mpk is similar to those of pirfenidone 100mpk, suggesting that eupatilin is a more potent anti-fibrotic agent. As before, pirfenidone 100mpk was associated with a lesser amount of TGF production in comparison with eupatilin 200mpk ( Figure 3C ), again suggesting that the MOA of pirfenidone involves decreasing the production of TGF in the lung. Nevertheless, eupatilin 100mpk or 200 mpk was also able to significantly inhibit TGF production. Eupatilin has been reported to be efficiently absorbed into the upper GI tract and appears in plasma within 1 hr of ingestion, and is also readily detected in lung tissue lysates (Ji et al., 2004) . We found that glucuronide-eupatilin was the major metabolite in plasma and excreted in urines ( Figure S8A ) whereas free eupatilin remained predominated in lung tissues. No glucouronide-eupatilin was detected by NMR. This observation suggests that orally administered eupatilin is rapidly disseminated to the lung via glucuronidation presumably occurring in the liver followed by deconjugation of the glucuronide moiety in the lung. Lung tissues express high levels of deconjugating enzymes (Strauss and Barbieri, 2014) . Eupatilin existed in the lung exclusively as the free form but at concentrations at least 50-fold lower than those of pirfenidone in terms of molar concentrations, suggesting that eupatilin is an extremely potent drug against lung fibrosis as seen in Figure S8B . Pirfenidone is hepatotoxic at high concentrations (Verma et al., 2017) , whereas the toxicity of eupatilin remains unknown. To explore this issue, we performed a full Reversion of fibrosis by eupatilin set of liver function tests using mouse plasma. As shown in Figure S9 , we detected no hepatotoxicity from mice treated with either pirfenidone 100mpk or eupatilin200mpk, suggesting that eupatilin does not elicit hepatotoxicity.
To determine whether eupatilin has anti-fibrotic efficacy during lung fibrosis, we performed an intervention test using BILF model, as schematized in Figure S10A . Soluble collagen production, collagen histomorphometry and TGF production was measured in the lung lysates. We observed significant reductions in collagen levels at eupatilin 100 and 200mpk. As such, pirfenidone 100mpk also had significant anti-fibrotic activity ( Figure   S10B and S10C), which seemed to be little more efficient than eupatilin in this particular intervention setting. Consistent with the prior therapeutic efficacy BILF test, inhibition of TGF production by pirfenidone 100mpk was higher than that of eupatilin 200mpk ( Figure   S10D ). The inhibitory activity by eupatilin 100mpk did not meet a statistical significance.
Eupatilin or pirfenidone produced a comparable cell regeneration potential observed by histological staining ( Figure S10E ). This observation indicates that MOA of eupatilin or pirfenidone may also different in vivo, recapitulating the results of the in vitro fibrogenesis assays in ONGHEPA1 cells.
Specific carbons of the CS and chemical residues are critical for anti-fibrogenic effects
The CS of eupatilin, shown by the highlighted carbons in Figure 4A , is linked to a phenyl ring coupled to two methoxy residues. The critical carbon residues for anti-fibrogenic potential are represented in colored fonts: C2 (yellow), C3 (purple), C6 (red) and C7 (green).
Next, we selected 34 CDs based on chemical similarities to eupatilin, classified into five chemical groups (A through E), and evaluated their anti-fibrogenic effects ( Figure 4E ). Among them, three CDs had anti-fibrogenic activity: eupatilin; ONGE200, also known as hispidulin;
Reversion of fibrosis by eupatilin and ONGA200, also known as jaceosidin. The latter two compounds are the most closely chemically related to eupatilin among the CDs tested. All of these compounds belong to group A, whose members differ in terms of the chemical residues coupled to the phenyl ring. Eupatilin and ONGE200 had marked anti-fibrotic effects ( Figure S11A ), whereas ONGA300 was cytotoxic at 50 M ( Figure S11B ). ONGI300, in which two hydroxy groups are coupled to the phenyl ring, had weak anti-fibrogenesis activity and promoted cell death, suggesting that chemical alteration of the phenyl ring affects anti-fibrotic activity ( Figure S11C ).
To explore the importance of the eight carbons of the CS in terms of structure-function relationship, two anti-fibrotic CDs (eupatilin and ONGE200) were brought into focus along with the remaining 33 CDs. When a methoxy residue was coupled to C3, as in ONGH300, the anti-fibrotic effect was eliminated and toxicity was apparent ( Figure 4C ). In comparison with ONGE200, ONGI200 (also known as apigenin) lacks only the methoxy group coupled to C6. ONGI200 had no anti-fibrotic effect, suggesting that C6 is an important constituent of the CS and that methoxylation of this position is necessary to prevent fibrosis ( Figure 4D ). We also noticed that ONGC200, in which the hydroxy residue at C2 of ONGE200 is replaced with a methoxy group, completely lost the anti-fibrotic effect, suggesting the C7 is also a critical component of the CS ( Figure S12A ). In addition, methoxylation at C2 of ONGA300, yielding a compound equivalent to ONGH300, abolished anti-fibrotic capacity, suggesting that the presence of a bulky group at C2 may affect anti-fibrogenic potential ( Figure S12B ). The same held true for ONGD400, a highly cytotoxic stereoisomer of ONGH300 in which C3 is methoxylated ( Figure S12C ). The chemical residues affecting anti-fibrotic potential are detailed in Figure 4E . Taken together, our data confirm that chemical modifications on the CS are only tolerated at specific carbons, indicating a stringent structure-activity relationship in regard to the anti-fibrogenic effects of these compounds.
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Reprogramming of the EMT by eupatilin may be responsible for anti-fibrosis
We next asked whether eupatilin blocks EMT induced by TGF. To this end, we stimulated ONGHEPA1 cells with TGF or TGF plus eupatilin, and then conducted global gene expression analyses by RNA-seq. Using a bioinformatics approach, we constructed an unbiased interactome that contained several notable hubs, including the collagen gene family (Col11a1) and the genes encoding components of the cytoskeleton (Actin  smooth muscle aorta, Troponin 1 and 2, Tropomyosin 2, Myosin-heavy chain 1 and Myosin-light chain 9, and Laminin 4) ( Figure S14 ). Notably, integrin 1 and integrin 3 played pivotal roles in connecting these hubs. Expression of Slug, a major transcription factor deeply involved in the EMT, was inhibited by eupatilin. Two cell cycle protein hubs, especially Cdk4 and c-Fos, seem to be pronounced, suggesting that the growth arrest effect on DHLFs by eupatilin could be explained. Several genes encoding receptors, including members of the semaphorin receptor family, a cholesterol receptor (Vldr), and CD44, formed significant hubs. One notable signaling molecule associated with eupatilin-mediated reprogramming of the EMT might be adenylate cyclase 9 (Adcy9), which is involved in small G-protein activation. To identify the most critical genes involved in reprogramming EMT by eupatilin, we identified a gene set that was maximally induced by TGF and maximally repressed by eupatilin. The resultant gene were 103 genes (data not shown). 12. The vast majority of these genes are involved in promoting EMT. For an instance, follistatin-like 1 (Fstl1) plays a pivotal role in pulmonary fibrosis (Dong et al., 2015) , and deficiency of Fstl1 completely protects mice from bleomycin-induced lung fibrosis, consistent with the downregulation of Fstl1 by eupatilin. These eupatilin-repressible genes could be new molecular targets for fibrosis.
In conclusion, these observations indicate that eupatilin curbs lung fibrosis by primarily by reprogramming EMT, altering cell shapes and, cell growth arrest and, to a lesser extent than pirfenidone, inhibition of TGF production. Therefore, eupatilin could be used for monotherapy or in combinatorial therapy with pirfenidone, with the goal of achieving a synergistic efficacy against IPF. 
RNA-seq processing, differential gene expression analysis, and interactome analysis
Processed reads were mapped to the Mus musculus reference genome (Ensembl 77) using Tophat and Cufflink with default parameters (Trapnell et al., 2012) . Differential analysis was performed using Cuffdiff (Trapnell et al., 2012) using default parameters. Further, FPKM values from Cuffdiff were normalized and quantitated using the R Package Tag Count
Comparison (TCC) (Sun et al., 2013) to determine statistical significance (e.g., P values) and differential expression (e.g., fold changes). Gene expression values were plotted in various ways (i.e., Scatter, MA, and Volcano plots), using fold-change values, using an R script developed in-house. The protein interaction transfer procedure was performed using the STRING database (Szklarczyk et al., 2011) with the differentially expressed genes. A 60 Gb sequence was generated, and 10,020 transcripts were read and compared. The highestconfidence interaction score (0.9) was applied from the Mus musculus species, and information about interacts were obtained based on text mining, experiments, and databases (http://www.string-db.org/).
Effects of drugs on bleomycin-induced lung tissue fibrosis
C57BL/6J mice were anesthetized by inhalation of 70% N2O and 30% O2 gas containing 1.5% isoflurane. Fifty microliters of bleomycin solution in distilled water was directly injected into the lungs, all at once, via the aperture. Immediately after injection, the mice were allowed to recover from the anesthetic, and then housed in normal cages.
Bleomycin (0.03U BLM in 50µl saline) was administered once using a visual instillobot.
Twelve days after the administration of bleomycin, eupatilin was forcibly nasally administered via a micropipette, once a day (five times a week) for 1 week. Eupatilin was dissolved in DPBS buffer (containing 1% DMSO), and 1 ml/kg was administered based on the most recent body weight. For 2 to 3 days after administration of eupatilin, mice were monitored for toxic symptoms or death, but no abnormal symptoms were observed. Three mice per test group were selected, and their lung tissues were excised. The lung tissues were stained with Masson's trichrome and observed under a microscope. Results were expressed
as mean values and standard deviations. One hour before sacrifice, a final dose of eupatilin or pirfenidone was administered for plasma or lung PK. The bleomycin-treated mice exhibited a rapid decline in weight, but the sham control behaved normally. Eupatilin-or pirfenidone-administered mice exhibited weight gain from day 3 onward. Control and eupatilin-treated mice data were compared using Student's t-test. "Differences between samples were considered statistically significant when p<0.05.
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Supplemental information Experimental Procedures
Flow cytometry
Cell pellets were suspended in PBS supplemented with 1% FBS and stained with antibodies against CD29, CD44, CD45, CD71, CD90, CD106, and CD117. All antibodies were obtained from BD Biosciences (San Jose, CA, USA). Labeled cells were analyzed on a flow cytometer (FC500, Beckman Coulter, Fullerton, CA, USA).
Cell viability assay
Cells were treated with TGFβ and the indicated concentrations of eupatilin (or other CDs) for 24 hr. Cell viability was measured using the CCK-8 kit (Dojindo Molecular Technologies, Tokyo, Japan).
Immunostaining
For immunofluorescence staining, ONGHEPA1 cells were grown on 8-well glass chamber slides (LabTek II, Thermo Fisher, Rochester, NY, USA) and fixed with methanol at -80C for 2 hr. After washing with PBS, cells were blocked and permeabilized by incubation at room temperature for 2 hr in PBS/5% FBS with 0.1% Triton X-100. After incubation with primary antibodies at 4C overnight, cells were washed, stained with dye-conjugated secondary antibodies, and incubated at room temperature for 2 hr. GATA4 (Santa Cruz Biotechnology, Dallas, TX, USA) and cytokeratin 18 (Santa Cruz Biotechnology) were used as markers of endoderm and endothelial cells, respectively. Nuclei were counterstained with DAPI. ONGHEPA1 cells were treated with TGFβ for 24 hr in the presence or absence of the indicated compounds. Anti-fibrotic activities were monitored by light microscopy. Three chromones (ONGC200, ONGH300, and ONGD400) exhibited no anti-fibrotic activities. 
TGF-β Medium
